
The topical synthetic peptide receives orphan drug and fast track status and enters phase 2 as a first-in-class treatment for a rare degenerative corneal disease.

The topical synthetic peptide receives orphan drug and fast track status and enters phase 2 as a first-in-class treatment for a rare degenerative corneal disease.

Yale School of Medicine researchers outline their findings and the methods of their researcher in an exclusive interview with Optometry Times.

A pilot study shows that analyzing how the cornea moves under air-puff stimulation may improve early keratoconus detection.

The university received $29.8 million through the state's Amended Fiscal Year 2026 Budget to renovate the Highway 301 building in Statesboro and create a facility to house the new program.

The product is expected to be available in stores and online at Amazon, CVS, Target and Walgreens by the end of June 2026.

The resubmission follows a successful appeal by the company with the Office of New Drugs (OND).

Host Hamza Shah, OD, MS, FAAO, is joined by Kaleb Abbott, OD, MS, to discuss eye care terminology, inspired by Abbott and Pucker's paper, "It's time to retire the terms artificial tears and rewetting drops: A call for accurate terminology and updated clinical usage in eye care."

The benefits of consistent physical activity have been demonstrated for a host of systemic conditions.

Kevin J. Kovach, MD, and Giannie Castellanos, OD, gave their insights this season on what helps build referral trust and long-lasting comanagement relationships.

The next-generation FSYX ocular pressure adjusting pump adds wireless connectivity to transmit patient usage data to prescribing practices.

Healthy adults showed stable tear and meibum lipid composition from morning to evening in a prospective lipidomic study.

The FDA's OND found substantial evidence of effectiveness for bevacizumab-vikg in nAMD, clearing the way for a BLA resubmission in June 2026 and a decision expected within 60 days.

The study, led by researchers at Keio University School of Medicine, measured near add power in 6258 patients aged 40 to 79.

Upsher-Smith launched generic cyclosporine ophthalmic emulsion 0.05% in the US for tear production in inflammatory dry eye.

The review analyzed 46 reports from 43 unique studies.

For Erin Tomiyama, OD, PhD, FAAO, managing myopia in pediatric patients involves decisions that extend well beyond updating a glasses prescription.

The study reviewed 1440 peer-reviewed journal articles indexed in the Web of Science Core Collection between 2010 and 2025.


The device, described in a new study, uses a technique called temporal interference-based transcorneal electrical stimulation, or TI-TES.

Mitch Ibach, OD, FAAO; Nate Lighthizer, OD, FAAO; and Austin Lifferth, OD, FAAO, share practical insights on identifying early disease and more.

NUS researchers report that plant-based photosynthetic nanoparticles restored corneal NADPH levels and reversed damage within 5 days in preclinical dry eye.

Across mild, moderate, and severe disease, 3 cases show how timely glaucoma intervention can reduce medications and preserve sight.

Mitch Ibach, OD, FAAO; Nate Lighthizer, OD, FAAO; and Austin Lifferth, OD, FAAO, discuss how they evaluate patients with borderline findings but significant risk factors

New Turkish study links sleeve gastrectomy weight loss to clearer cornea and lens, lower eye pressure, and widened anterior chamber in 6 months.

AMD affects approximately 28 million people in the US and is a leading cause of vision loss among older adults.

A rare case study demonstrates the importance of vaccination to reduce the incidence of severe complications associated with HZO.

Avacincaptad pegol may help preserve driving-related vision in geographic atrophy, but post hoc data did not reach statistical significance.

At ARVO Michael Siatkowski, MD, and Jody Summers, PhD, stopped to discuss the rising rates of myopia in children and if anti-inflammatory drugs could play a role in slowing progression.

Danish JAMA Dermatology trials show short-term topical or oral corticosteroids don’t raise intraocular pressure, easing glaucoma worries in atopic dermatitis care.

Andrew Pucker, OD, PhD, FAAO, FSLS, FBCLA, talked about a recent paper in which he proposed the renaming of artificial tears and rewetting drops to lubricating drops.